Axovant to pull plug on Alzheimer's drug after key study fails

Reuters – Drug developer Axovant Sciences Ltd said it would stop testing its lead drug in Alzheimer’s after it failed to meet the main goals of a late-stage trial, underlining the challenges in developing treatments for the memory-robbing disease.

The company’s shares tumbled 74.7 percent to a record low of $6.13 in morning trading on Tuesday.

Axovant’s once-daily oral drug, intepirdine, belongs to a class of drugs called 5-HT6 antagonist, which works by blocking the 5-HT6 receptor to help release acetylcholine, a neurotransmitter needed for normal cognition.

The latest failure raised serious doubts about the mechanism’s potential as a treatment for Alzheimer‘s, the most common form of dementia that affects about 5.5 million people in the United States.

Read more at Reuters.

News Image
Comparison illustration of normal brain versus Alzheimer's brain
Topics
Neuroscience
Action
Industry